Blood-based biomarkers of adverse perinatal outcomes in maternal obesity

Herrera, Tania T.; Garcia, Jillian L.; Britton, Gabrielle B.

doi:10.1080/14767058.2016.1271406

Cited by 4 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…As stated by Herrera et al [48], a better understanding for biological processes linking maternal obesity with adverse perinatal outcomes is needed. At present time, no biomarkers are fulfilling the criteria to be used in clinic to predict perinatal complications [48]. Although previous studies support theories of inflammatory pathways, actions of specific inflammatory mediators, and inflammatory properties of the placenta, much is unknown and more research is needed [48].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Maternal Blood-Based Protein Biomarkers in Relation to Abdominal Fat Distribution Measured by Ultrasound in Early Mid-Pregnancy

et al. 2022

View full text Add to dashboard Cite

The objective of this study was to examine the associations of early mid-pregnancy ultrasound measured visceral and subcutaneous fat depths with blood-based protein biomarkers. This was a cross-sectional study including 201 pregnant women at Uppsala University Hospital, Sweden. The mean age of the women was 31.0 years, and 57.7% were nulliparous. Maternal visceral and subcutaneous fat depths were measured by ultrasound at the early second-trimester anomaly scan. A non-fasting blood sample was collected in conjunction with the second-trimester anomaly scan, and the Olink cardiovascular II panel was used to measure 92 blood-based protein biomarkers in the sample. Cross-sectional associations of visceral and subcutaneous fat depths with blood-based protein biomarkers were examined using Mann–Whitney U tests with false discovery rate adjustments. In addition, linear regression analyses adjusting for maternal age, parity, and early pregnancy body mass index were performed. The results showed differences in one biomarker between women with elevated (≥ 52 mm) versus normal (< 52 mm) visceral fat depth, and in three biomarkers between women with elevated (≥ 22 mm) versus normal (< 22 mm) subcutaneous fat depth. Hence, levels of blood-based protein biomarkers differ between pregnant women with dissimilar body fat distributions, which might reflect disparities in biological pathways.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Maternal Blood-Based Protein Biomarkers in Relation to Abdominal Fat Distribution Measured by Ultrasound in Early Mid-Pregnancy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In this study, we found maternal prepregnancy overweight and obesity to be associated with overall stillbirth or neonatal death, and death due to specific causes such as placental dysfunction, umbilical cord complication, intrapartum events, and infection was more common in women with obesity. Although several biomarkers have been suggested to identify obese women at higher risk of pregnancy complications including stillbirth and neonatal death, none are considered clinically useful yet [ 63 , 64 ]. Ultrasound scans are today used for the screening of high-risk women, alone or in combination with biomarkers, but its specific application in stillbirth, especially in a broader population such as women with overweight or obesity, still needs to be proven in large clinical studies, which in itself is a great challenge due to the rarity of the outcome [ 64 ].…”

Section: Discussionmentioning

confidence: 99%

Cause-Specific Stillbirth and Neonatal Death According to Prepregnancy Obesity and Early Gestational Weight Gain: A Study in the Danish National Birth Cohort

et al. 2021

View full text Add to dashboard Cite

Maternal obesity is associated with impaired fetal and neonatal survival, but underlying mechanisms are poorly understood. We examined how prepregnancy BMI and early gestational weight gain (GWG) were associated with cause-specific stillbirth and neonatal death. In 85,822 pregnancies in the Danish National Birth Cohort (1996–2002), we identified causes of death from medical records for 272 late stillbirths and 228 neonatal deaths. Prepregnancy BMI and early GWG derived from an early pregnancy interview and Cox regression were used to estimate associations with stillbirth or neonatal death as a combined outcome and nine specific cause-of-death categories. Compared to women with normal weight, risk of stillbirth or neonatal death was increased by 66% with overweight and 78% with obesity. Especially deaths due to placental dysfunction, umbilical cord complications, intrapartum events, and infections were increased in women with obesity. More stillbirths and neonatal deaths were observed in women with BMI < 25 and low GWG. Additionally, unexplained intrauterine death was increased with low GWG, while more early stillbirths were seen with both low and high GWG. In conclusion, causes of death that relate to vascular and metabolic disturbances were increased in women with obesity. Low early GWG in women of normal weight deserves more clinical attention.

show abstract

“…These biomarkers could potentially be used as screening tools to identify population at risk, and to predict outcomes for the mother and offspring. However, the applicability of these biomarkers in a clinical setting is limited and requires more information, particularly among the obese population [30]. For example, it is generally known that low folate levels increase the risk of neural tube defects in offspring, while first trimester inflammatory cytokines are associated with increased risk of preterm birth among obese women [31][32][33].…”

Section: Introductionmentioning

confidence: 99%

Periconceptional biomarkers for maternal obesity: a systematic review

Hojeij

Rousian

Sinclair

et al. 2022

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Periconceptional maternal obesity is linked to adverse maternal and neonatal outcomes. Identifying periconceptional biomarkers of pathways affected by maternal obesity can unravel pathophysiologic mechanisms and identify individuals at risk of adverse clinical outcomes. The literature was systematically reviewed to identify periconceptional biomarkers of the endocrine, inflammatory and one-carbon metabolic pathways influenced by maternal obesity. A search was conducted in Embase, Ovid Medline All, Web of Science Core Collection and Cochrane Central Register of Controlled Trials databases, complemented by manual search in PubMed until December 31st, 2020. Eligible studies were those that measured biomarker(s) in relation to maternal obesity, overweight/obesity or body mass index (BMI) during the periconceptional period (14 weeks preconception until 14 weeks post conception). The ErasmusAGE score was used to assess the quality of included studies. Fifty-one articles were included that evaluated over 40 biomarkers. Endocrine biomarkers associated with maternal obesity included leptin, insulin, thyroid stimulating hormone, adiponectin, progesterone, free T4 and human chorionic gonadotropin. C-reactive protein was associated with obesity as part of the inflammatory pathway, while the associated one-carbon metabolism biomarkers were folate and vitamin B12. BMI was positively associated with leptin, C-reactive protein and insulin resistance, and negatively associated with Free T4, progesterone and human chorionic gonadotropin. Concerning the remaining studied biomarkers, strong conclusions could not be established due to limited or contradictory data. Future research should focus on determining the predictive value of the optimal set of biomarkers for their use in clinical settings. The most promising biomarkers include leptin, adiponectin, human chorionic gonadotropin, insulin, progesterone and CRP.

show abstract

Blood-based biomarkers of adverse perinatal outcomes in maternal obesity

Abstract: There is a critical need for reliable blood-based biomarkers associated with an increased risk of adverse perinatal outcomes in obese pregnant women.

Cited by 4 publications

References 29 publications

Maternal Blood-Based Protein Biomarkers in Relation to Abdominal Fat Distribution Measured by Ultrasound in Early Mid-Pregnancy

Maternal Blood-Based Protein Biomarkers in Relation to Abdominal Fat Distribution Measured by Ultrasound in Early Mid-Pregnancy

Cause-Specific Stillbirth and Neonatal Death According to Prepregnancy Obesity and Early Gestational Weight Gain: A Study in the Danish National Birth Cohort

Periconceptional biomarkers for maternal obesity: a systematic review

Contact Info

Product

Resources

About